Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;41(4):677-680.
doi: 10.1007/s10096-021-04397-x. Epub 2022 Jan 28.

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants

Laurent Poirel  1   2   3 , Mustafa Sadek  1   4 , Ayda Kusaksizoglu  1 , Patrice Nordmann  5   6   7   8
Affiliations

Co-resistance to ceftazidime-avibactam and cefiderocol in clinical isolates producing KPC variants

Laurent Poirel et al. Eur J Clin Microbiol Infect Dis. 2022 Apr.

Abstract

Cefiderocol (FDC) and ceftazidime-avibactam (CZA) are among the latest generation of commercialized antibiotics against carbapenem-resistant Gram negatives. However, emergence of CZA resistance is being increasingly reported, involving different KPC variants in Enterobacterales. By analyzing two CZA-resistant KPC-3 clinical variants, KPC-41 and KPC-50, we showed that KPC-41, and to a lesser extent KPC-50, may also have an impact on susceptibility to FDC leading to a cross-resistance. This feature highlights that a susceptibility testing to FDC is mandatory prior any clinical use of FDC for treating infections due to KPC producers.

Keywords: Cefiderocol; Ceftazidime-avibactam; Cross-resistance; KPC-41; KPC-50.

PubMed Disclaimer

References

    1. Munoz-Price LS, Poirel L, Bonomo RA et al (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13(9):785–796. https://doi.org/10.1016/S1473-3099(13)70190-7 - DOI - PubMed - PMC
    1. Kazmierczak KM, Biedenbach DJ, Hackel M et al (2016) Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60(8):4490–4500. https://doi.org/10.1128/AAC.00107-16 - DOI - PubMed - PMC
    1. Zhanel GG, Lawson CD, Adam H et al (2013) Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs 73(2):159–177. https://doi.org/10.1007/s40265-013-0013-7 - DOI - PubMed
    1. Sharma R, Park TE, Moy S (2016) Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant Gram-negative organisms. Clin Ther 38(3):431–444. https://doi.org/10.1016/j.clinthera.2016.01.018 - DOI - PubMed
    1. Barnes MD, Winkler ML, Taracila MA et al (2017) Klebsiella pneumoniae carbapenemase-2 (KPC-2), substitutions at ambler position Asp179, and resistance to ceftazidime-avibactam: unique antibiotic-resistant phenotypes emerge from β-lactamase protein engineering. MBio 8(5):e00528-e617. https://doi.org/10.1128/mBio.00528-17 - DOI - PubMed - PMC

LinkOut - more resources